Inovio Pharmaceuticals, Inc. (INO)
NASDAQ: INO · Real-Time Price · USD
2.380
-0.270 (-10.19%)
At close: Sep 12, 2025, 4:00 PM EDT
2.390
+0.010 (0.42%)
After-hours: Sep 12, 2025, 7:53 PM EDT
Inovio Pharmaceuticals Revenue
Inovio Pharmaceuticals had revenue of $182.34K in the twelve months ending June 30, 2025, down -69.19% year-over-year. In the year 2024, Inovio Pharmaceuticals had annual revenue of $217.76K, down -73.83%.
Revenue (ttm)
$182.34K
Revenue Growth
-69.19%
P/S Ratio
693.66
Revenue / Employee
$1,361
Employees
134
Market Cap
126.48M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 217.76K | -614.25K | -73.83% |
| Dec 31, 2023 | 832.01K | -9.43M | -91.89% |
| Dec 31, 2022 | 10.26M | 8.49M | 478.23% |
| Dec 31, 2021 | 1.77M | -5.64M | -76.05% |
| Dec 31, 2020 | 7.41M | 3.30M | 80.24% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
INO News
- 7 days ago - Inovio Pharmaceuticals, Inc. (INO) Presents At H.C. Wainwright 27th Annual Global Investment Conference (Transcript) - Seeking Alpha
- 17 days ago - INOVIO to Begin Rolling Submission of BLA for INO-3107 for the Treatment of RRP in Adults - PRNewsWire
- 18 days ago - INOVIO to Participate in the H.C. Wainwright 27th Annual Global Investment Conference - PRNewsWire
- 4 weeks ago - Inovio Pharmaceuticals, Inc. (INO) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - INOVIO Reports Second Quarter 2025 Financial Results and Recent Business Highlights - PRNewsWire
- 4 weeks ago - Data Published in The Laryngoscope shows INO-3107 Resulted in Long-Term Surgery Reduction in Recurrent Respiratory Papillomatosis (RRP) - PRNewsWire
- 5 weeks ago - INOVIO to Report Second Quarter 2025 Financial Results on August 12, 2025 - PRNewsWire
- 2 months ago - INOVIO to Present at Upcoming Scientific Conference - PRNewsWire